Claims for Patent: 8,058,418

Summary for Patent: 8,058,418

Title:	Polynucleotides encoding heavy and light chains of antibodies to OPGL
Abstract:	Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.
Inventor(s):	Boyle; William J. (Thousand Oaks, CA), Martin; Francis H. (Newbury Park, CA), Corvalan; Jose R. (Foster City, CA), Davis; C. Geoffrey (Burlingame, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA)
Application Number:	11/981,664
Patent Claims:	1. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 2. The composition of claim 1, wherein the first polynucleotide and the second polynucleotide are part of the same nucleic acid molecule. 3. The composition of claim 1, wherein the first polynucleotide and the second polynucleotide are operably linked such that they encode a single-chain antibody. 4. The composition of claim 3, wherein the single-chain antibody is a single-chain Fv antibody. 5. The composition of claim 1, which encodes a Fab antibody. 6. The composition of claim 1, which encodes a Fab' antibody. 7. The composition of claim 1, which encodes a F(ab').sub.2 antibody. 8. The composition of claim 1, which encodes a fully human antibody. 9. A vector comprising at least one polynucleotide selected from a first polynucleotide that encodes the amino acid sequence of SEQ ID NO: 13 and a second polynucleotide that encodes the amino acid sequence of SEQ ID NO: 14. 10. The vector of claim 9, wherein the vector comprises at least one polynucleotide selected from a first polynucleotide that encodes the amino acid sequence of SEQ ID NO: 2 and a second polynucleotide that encodes the amino acid sequence of SEQ ID NO: 4. 11. A host cell comprising at least one vector of claim 9. 12. A method of producing an antibody that interacts with OPGL, comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14, and wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 13. The method of claim 12, wherein the first polynucleotide encodes the amino acid sequence of SEQ ID NO: 2 and the second polynucleotide encodes the amino acid sequence of SEQ ID NO: 4. 14. The method of claim 12, wherein the first polynucleotide encodes an amino acid sequence comprising the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the second polynucleotide encodes an amino acid sequence comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 15. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 13 and the second polynucleotide encodes a light chain, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 16. The composition of claim 15, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467. 17. The composition of claim 15, wherein the first polynucleotide encodes a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467. 18. The composition of claim 15, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14. 19. The composition of claim 16, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14. 20. The composition of claim 17, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14. 21. The composition of claim 15, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 22. The composition of claim 17, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 23. The composition of claim 15, wherein the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 24. The composition of claim 16, wherein the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 25. The composition of claim 15, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 26. The composition of claim 15, wherein the first polynucleotide encodes a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 27. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain and the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 28. The composition of claim 27, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 29. The composition of claim 27, wherein the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 30. A method of producing an antibody that interacts with OPGL, comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:13 and the second polynucleotide encodes a light chain, and wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 31. A method of producing an antibody that interacts with OPGL, comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO: 14, and wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 32. The method of claim 31, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 13. 33. An antibody produced by the method of any one of claims 12, and 30, and 31. 34. The composition of claim 15 or 27, wherein the first polynucleotide and the second polynucleotide are part of the same nucleic acid molecule. 35. The composition of claim 15 or 27, wherein the first polynucleotide and the second polynucleotide are operably linked such that they encode a single-chain antibody. 36. The composition of claim 35, wherein the single-chain antibody is a single-chain Fv antibody. 37. The composition of claim 15 or 27, which encodes a Fab antibody. 38. The composition of claim 15 or 27, which encodes a Fab' antibody. 39. The composition of claim 15 or 27, which encodes a F(ab').sub.2 antibody. 40. The composition of claim 15 or 27, which encodes a fully human antibody.

Details for Patent 8,058,418

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	8,058,418	2021-06-26
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	8,058,418	2021-06-26

International Patent Family for US Patent 8,058,418

Country	Patent Number	Estimated Expiration
Argentina	034637
Australia	2002320157
Australia	2008261137
Australia	2012216429
Australia	2013204100
Austria	E464068